{
    "Clinical Trial ID": "NCT00915018",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Neratinib + Paclitaxel",
        "  Neratinib + Paclitaxel",
        "  Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "INTERVENTION 2: ",
        "  Trastuzumab + Paclitaxel",
        "  Trastuzumab + Paclitaxel",
        "  Trastuzumab: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  ErbB-2 positive locally recurrent or metastatic breast cancer",
        "  Eastern Cooperative Oncology Group (ECOG) 0-2",
        "  Measurable disease",
        "  Availability of tumor tissue for HER2 status confirmation",
        "Exclusion Criteria:",
        "  Prior systemic anti-cancer therapy other than endocrine therapy for locally recurrent or metastatic disease",
        "  Prior erbB-2 inhibitor other than trastuzumab or lapatinib in the neoadjuvant or adjuvant setting",
        "  Progression/recurrence within 12 months after completion of adjuvant or neoadjuvant therapy",
        "  History of heart disease",
        "  History of gastrointestinal disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival",
        "  Defined as the interval from the date of randomization until the first date on which recurrence or progression, or death due to any cause, is documented, censored at the last assessable evaluation or at the initiation of new anticancer therapy.",
        "  Time frame: From randomization to disease progression or death, assessed up to 5.3 years",
        "Results 1: ",
        "  Arm/Group Title: Neratinib + Paclitaxel",
        "  Arm/Group Description: Neratinib + Paclitaxel",
        "  Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Overall Number of Participants Analyzed: 242",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  12.9        (11.1 to 14.9)",
        "Results 2: ",
        "  Arm/Group Title: Trastuzumab + Paclitaxel",
        "  Arm/Group Description: Trastuzumab + Paclitaxel",
        "  Trastuzumab: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.",
        "  Overall Number of Participants Analyzed: 237",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  12.9        (11.1 to 14.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 67/240 (27.92%)",
        "  Anaemia 0/240 (0.00%)",
        "  Febrile neutropenia 1/240 (0.42%)",
        "  Leukopenia 2/240 (0.83%)",
        "  Neutropenia 1/240 (0.42%)",
        "  Thrombocytopenia 0/240 (0.00%)",
        "  Atrial fibrillation 0/240 (0.00%)",
        "  Cardiac failure congestive 2/240 (0.83%)",
        "  Cardiac tamponade 1/240 (0.42%)",
        "  Cardio-respiratory arrest 1/240 (0.42%)",
        "  Left ventricular dysfunction 0/240 (0.00%)",
        "Adverse Events 2:",
        "  Total: 56/234 (23.93%)",
        "  Anaemia 1/234 (0.43%)",
        "  Febrile neutropenia 0/234 (0.00%)",
        "  Leukopenia 0/234 (0.00%)",
        "  Neutropenia 0/234 (0.00%)",
        "  Thrombocytopenia 1/234 (0.43%)",
        "  Atrial fibrillation 1/234 (0.43%)",
        "  Cardiac failure congestive 0/234 (0.00%)",
        "  Cardiac tamponade 0/234 (0.00%)",
        "  Cardio-respiratory arrest 0/234 (0.00%)",
        "  Left ventricular dysfunction 1/234 (0.43%)"
    ]
}